Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MEREO BIOPHARMA (MREO : NSDQ)

• Company Description    Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company's product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom. Number of Employees: 49

• Price / Volume Information    Yesterday's Closing Price: $0.44 Daily Weekly Monthly 20 Day Moving Average: 1,858,861 shares Shares Outstanding: 116.98 (millions) Market Capitalization: $51.09 (millions) Beta: 2.00 52 Week High: $3.75 52 Week Low: $0.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -50.99% -46.30% 12 Week -66.92% -64.10% Year To Date -72.71% -67.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CAVENDISH PLACE FOURTH FLOOR - LONDON,X0 W1G0QF GBR ph: 44-33-3023-7300 fax: - investors@mereobiopharma.com http://www.mereobiopharma.com

• General Corporate Information    Officers Denise Scots-Knight - Chief Executive Officer and Director Peter Fellner - Chairman Christine Fox - Chief Financial Officer Jeremy Bender - Director Anders Ekblom - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 589492107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 06/30/22 Share - Related Items Shares Outstanding: 116.98 Most Recent Split Date: (:1) Beta: 2.00 Market Capitalization: $51.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/30/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.42 Price/Cash Flow: 2.78 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 7.92 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - 7.92 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - 39.06 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 1.03 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.16 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - 14.05 09/30/21 - -

Powered by Zacks Investment Research ©